MV-NIS

AXP000113.1 · Oncolytic virus

Platform
measles virus (Edmonston-NSe vaccine lineage)
Originator
Mayo Clinic
Sponsor
Mayo Clinic

Names

NameTypeSource
MV-NISpreferred name, codecurator, ncit
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symportersynonymncit

Virus

Role
Oncolytic
Family
Paramyxoviridae
Virus
measles morbillivirus (NCBI Taxonomy 11234)
Strain
Edmonston-NSe vaccine lineage
Replication
replicating
Modifications
NIS cassette inserted for imaging and radioiodine therapy
Transgenes
SLC5A5
Route
intraperitoneal, intravenous
Source
evidence

Cross-references

NCI Thesaurus
C66942

Approvals

No regulatory approval recorded.

Clinical trials (11)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03171493Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical CystectomyCompletedPhase 12018-07-202021-02-118Urothelial Carcinoma
NCT02919449Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With AtezolizumabTerminatedPhase 12017-08-032018-01-192Recurrent Non-Small Cell Lung Cancer
NCT02700230Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by SurgeryCompletedPhase 12017-03-222024-04-179Metastatic Malignant Peripheral Nerve Sheath Tumor; Neurofibromatosis Type 1; Recurrent Malignant Peripheral Nerve Sheath Tumor
NCT02962167Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRTCompletedPhase 12017-02-222023-05-1034Atypical Teratoid/Rhabdoid Tumor; Medulloblastoma Recurrent; Medulloblastoma, Childhood, Recurrent
NCT02364713MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal CancerTerminatedPhase 22015-03-132022-01-1317Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Primary Peritoneal Transitional Cell Carcinoma; Primary Peritoneal Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
NCT02192775UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles VirusCompletedPhase 22015-032019-08-202Multiple Myeloma
NCT02068794MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube CancerActive not recruitingPhase 1/22014-04-252024-03-1534Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Malignant Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
NCT01846091Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast CancerCompletedPhase 12013-04-092019-09-1812Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Head and Neck Squamous Cell Carcinoma; Invasive Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Head and Neck Carcinoma; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma
NCT01503177Intrapleural Measles Virus Therapy in Patients With Malignant Pleural MesotheliomaCompletedPhase 12011-112019-04-1115Recurrent Malignant Mesothelioma; Stage IA Malignant Mesothelioma; Stage IB Malignant Mesothelioma; Stage II Malignant Mesothelioma; Stage III Malignant Mesothelioma; Stage IV Malignant Mesothelioma
NCT00450814Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple MyelomaCompletedPhase 1/22006-11-302018-07-1048Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
NCT00408590Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedPhase 12004-04-192012-0837Ovarian Cancer; Primary Peritoneal Cavity Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40540301Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005.Clinical cancer research : an official journal of the American Association for Cancer Research2025name in abstract: MV-NIS
PMID 33641042Systemic Options for Malignant Peripheral Nerve Sheath Tumors.Current treatment options in oncology2021cited by trial NCT02700230
PMID 32327728Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.Leukemia2020name in abstract: MV-NIS
PMID 28439108Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.Leukemia2017name in abstract: MV-NIS
PMID 24835528Remission of disseminated cancer after systemic oncolytic virotherapy.Mayo Clinic proceedings2014name in abstract: MV-NIS

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41741902Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors.Journal of neuro-oncology2026name in abstract: MV-NIS
PMID 42625927Updated oncolytic viruses for the treatment of bladder cancer: a systematic review.Iranian journal of microbiology2026name in abstract: MV-NIS
PMID 38941955Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures.EBioMedicine2024name in abstract: MV-NIS
PMID 37749907Oncolytic virotherapies for pediatric tumors.Expert opinion on biological therapy2023name in abstract: MV-NIS
PMID 35487285Clinical advances in oncolytic virotherapy for pediatric brain tumors.Pharmacology & therapeutics2022name in abstract: MV-NIS
PMID 36555262Therapeutic Applications for Oncolytic Self-Replicating RNA Viruses.International journal of molecular sciences2022name in abstract: MV-NIS
PMID 34830842The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma.Cancers2021name in abstract: MV-NIS
PMID 28228086Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.Current cancer drug targets2018name in abstract: MV-NIS
PMID 27604429Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice.Human gene therapy. Clinical development2016name in abstract: MV-NIS
PMID 27782084Measles to the Rescue: A Review of Oncolytic Measles Virus.Viruses2016name in abstract: MV-NIS
PMID 25398436Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.Cancer research2015name in abstract: MV-NIS
PMID 25843626Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.Gene2015name in abstract: MV-NIS
PMID 25394505Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma.Cancer gene therapy2014name in abstract: MV-NIS
PMID 22914495Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.Gene therapy2013name in abstract: MV-NIS
PMID 23849174Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2013name in abstract: MV-NIS
PMID 21753796Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors.Gene therapy2012name in abstract: MV-NIS
PMID 22185260Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS).Human gene therapy2012name in title: MV-NIS
PMID 22235810Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.Human gene therapy2012name in title: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
PMID 22790962Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.Cancer gene therapy2012name in abstract: MV-NIS
PMID 23134812Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine.BMC cancer2012name in abstract: MV-NIS
PMID 21703308Fluorescein and radiolabeled Function-Spacer-Lipid constructs allow for simple in vitro and in vivo bioimaging of enveloped virions.Journal of virological methods2011name in abstract: MV-NIS
PMID 20234340Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.Molecular therapy : the journal of the American Society of Gene Therapy2010name in abstract: MV-NIS
PMID 20651188Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer.AJR. American journal of roentgenology2010name in abstract: MV-NIS
PMID 19098211Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene.AJR. American journal of roentgenology2009name in abstract: MV-NIS
PMID 19169959Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.Current opinion in molecular therapeutics2009name in abstract: MV-NIS
PMID 19773744Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.Molecular therapy : the journal of the American Society of Gene Therapy2009name in abstract: MV-NIS
PMID 17971816Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.Clinical pharmacology and therapeutics2007name in title: MV-NIS
PMID 16328647Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor.Molecular imaging and biology2006name in abstract: MV-NIS
PMID 16551872Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.Clinical cancer research : an official journal of the American Association for Cancer Research2006name in abstract: MV-NIS
PMID 17053863In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography.Molecular imaging and biology2006name in abstract: MV-NIS
PMID 14604966Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.Blood2004name in abstract: MV-NIS

NIH grants

ProjectTitleOrganisationPIYearsLinked by
P50CA116201Project 3: Measles virus based immunovirotherapy in the treatment of metastatic breast cancerMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2016–2021name in abstract: MV-NIS
R01CA200507Optimizing Delivery of Oncolytic Measles Virus Strains with Cell CarriersMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2017–2020name in abstract: MV-NIS
R44CA221461INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCERVYRIAD, INC.RUSSELL, LUKE O.2017–2019name in abstract: MV-NIS
26120080000DCTD Biopharmaceutical DevelopmentLEIDOS BIOMEDICAL RESEARCH, INC.HEIMBROOK, DAVID2008–2018name in abstract: MV-NIS
R01CA196975First in-human PET imaging studies of NIS reporter [18F]BF4MAYO CLINIC ROCHESTERDEGRADO, TIMOTHY R.2016–2018name in abstract: MV-NIS
DP2CA195764Oncolytic Virotherapy in Hepatocellular CancerMAYO CLINIC ARIZONABORAD, MITESH2014–2016name in abstract: MV-NIS
P30CA015083Gene and Virus Therapy ProgramMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2014–2016name in abstract: MV-NIS
K23CA159391Anti-Tumor Immunity in Response to a Modified Vaccine Strain Measles VirusMAYO CLINIC ROCHESTERPEIKERT, TOBIAS2012–2015name in abstract: MV-NIS
P50CA108961Optimizing Measles Virotherapy in the Treatment of GliomasMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2004–2015name in abstract: MV-NIS
R01CA154348Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomasMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2011–2014name in abstract: MV-NIS
R01CA168719Measles Virotherapy for Multiple MyelomaMAYO CLINIC ROCHESTERRUSSELL, STEPHEN J2012–2014name in abstract: MV-NIS
P50CA136393Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian CancerMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2009–2013name in abstract: MV-NIS
R01CA100634Radiovirotherapy for Multiple MyelomaMAYO CLINIC ROCHESTERRUSSELL, STEPHEN J2003–2012name in abstract: MV-NIS
R01CA136547Optimizing Measles Virotherapy in the Treatment of Ovarian CancerMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2009–2012name in abstract: MV-NIS
R01CA125614Virotherapy for Relapsed Refractory Multiple MyelomaMAYO CLINIC ROCHESTERDISPENZIERI, ANGELA2006–2011name in abstract: MV-NIS
R44CA150283Virotherapy for Squamous Cell Carcinoma of the Head and NeckNISCO INTERNATIONAL, INC.QIAO, JIAN2010–2010name in abstract: MV-NIS
K08CA103859Image-guided Gene and Virotherapy for Pancreatic CancerMAYO CLINIC ROCHESTERCARLSON, STEPHANIE KAY2005–2009name in abstract: MV-NIS
N01CO12400-DCTD Biopharmaceutical Development 2007–2007name in abstract: MV-NIS

Notes

Edmonston-lineage measles virus encoding the thyroidal sodium iodide symporter (SLC5A5) for imaging and radiovirotherapy. Separate construct from MV-CEA, tested separately in humans. Also given inside mesenchymal stromal cells in a separate delivery study (carrier, not a separate construct).

How to cite

MV-NIS (AXP000113.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000113.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.